In the rapidly evolving landscape of cancer treatments, Aumseqa (aumolertinib) has emerged as a promising advancement against non-small cell lung cancer (NSCLC) characterized by EGFR mutations. Recently approved by the Medicines and Healthcare products Regulatory Agency (MHRA), Aumseqa is
The field of regenerative medicine has witnessed a groundbreaking development as an innovative clinical trial gets underway at Princess Alexandra Hospital. This trial focuses on the reconstruction of jawbones using advanced 3D-printed implants—marking a significant leap forward for both
With a background steeped in biopharmaceutical innovation, Ivan Kairatov is a leading expert in oncology therapeutics. His insights into the development and approval of new cancer treatments are invaluable, especially regarding the European Commission's recent decision on AstraZeneca's Calquence
Childhood cancer continues to be a daunting global health challenge, affecting around 400,000 children annually. Early diagnosis remains a cornerstone for improving the survival rate and quality of life for these young patients. In 2018, the World Health Organization (WHO) launched the Global
Recent European Union regulations have significantly reshaped the clinical trials landscape, positioning compliance as a competitive advantage for biopharmaceutical firms. With frameworks such as the EU General Data Protection Regulation (GDPR), the Artificial Intelligence (AI) Act, and the
Mission Bio has unveiled a groundbreaking technology that promises to redefine the landscape of precision oncology. The single-cell genotype and targeted gene expression assay, part of the well-regarded Tapestri Platform, has been introduced as the first commercial solution designed to deliver
